Mr. Stephen Van Deventer reports

PREVECEUTICAL ANNOUNCES UP-SIZED NON-BROKERED PRIVATE PLACEMENT

Further to the news release dated April 2, 2025, Preveceutical Medical Inc. will increase the size of its previously announced non-brokered private placement from $500,000 to $700,000, resulting in up to 23,333,333 units of the company at a price of three cents per unit. Each unit will be composed of one common share in the capital of the company and one-half of one share purchase warrant. Each warrant entitles the holder thereof to purchase an additional share at an exercise price of five cents per warrant share for a period of 24 months from the closing of the offering, subject to an acceleration right, whereby the expiry date of the warrants may be accelerated if the daily closing price of the shares equals or exceeds eight cents or greater on the Canadian Securities Exchange (or such other recognized securities exchange on which the shares may then trade) for a minimum of 10 consecutive trading days, in which event the company may accelerate the expiry of the warrants by giving notice by news release and, in such case, all of the then unexercised warrants will expire on the 30th day after the date on which the news release is disseminated.

The company intends to use the aggregate gross proceeds from the sale of the offering to pay outstanding payables, for operating expenses and for general working capital purposes. The company may pay finders' fees in connection with the offering.

Closing of the offering is subject to receipt of all necessary regulatory approvals, including from the CSE. All securities issued in relation to the offering will be subject to a hold period expiring four months and one day after the closing date, in accordance with applicable securities laws.

About Preveceutical Medical Inc.

Preveceutical is a health science company that develops innovative options for preventive and curative therapies, utilizing organic and nature identical products. Preveceutical aims to be a leader in preventive health sciences and currently has five research and development programs, including: dual gene therapy for curative and prevention therapies for diabetes and obesity; the Sol-gel program; nature identical peptides for treatment of various ailments; non-addictive analgesic peptides as a replacement to the highly addictive analgesics such as morphine, fentanyl and oxycodone; and a therapeutic product for treating athletes who suffer from concussions (mild traumatic brain injury).

We seek Safe Harbor.